#21 ·
Dear,
Regarding the lab results you shared, I have to point out that having both MPO and PR3 antibodies present at the same time—as seen in your case—is quite unusual. When results look like this, we always have to rule out an underlying infection or certain medications that might trigger such a pattern. To be honest, I’m pretty skeptical about this being ANCA vasculitis, though I can't rule it out entirely. As for antiphospholipid syndrome, my stance remains unchanged: seeing only positive antibodies isn't enough to confirm that diagnosis.
I see you've also had coagulation tests performed, specifically checking factors VII and X, along with Protein C and S levels. Those levels are low, which makes sense given that you're taking Warfarin, as indicated by your INR. Since Warfarin works by blocking the production of factors II, VII, IX, and X, it's expected that these levels would drop while on the medication. I’m not entirely sure why these specific tests were requested. It would make perfect sense if factors VII and IX, or Protein C and S, had been tested *before* starting Warfarin—that's how you determine if there's an existing risk for clots or subsequent embolisms. Your entire clinical picture seems centered around clotting and emboli, yet you haven't mentioned them, and thrombosis or embolism isn't listed in your diagnoses. That's a bit confusing.
Furthermore, some genetic testing was done, though not for antiphospholipid syndrome as I suspected, but for thrombophilia. You were identified as a heterozygote for PAI-1, meaning you have the 4G/5G genotype. The highest risk for thrombosis lies with those who have the 4G/4G genotype; for someone with your 4G/5G profile, that risk is significantly lower.
I also noticed testing for the I/D polymorphism in intron 16 of the ACE gene. In individuals with the homozygous D/D genotype, there is a link to higher blood pressure and thickened vessel walls. What's puzzling here is that the report lists "I/D homozygote," which is a contradiction in terms. A homozygote is either I/I or D/D; I/D is a heterozygote. This suggests either a clerical error or an incomplete result.
Additionally, there was testing for a Factor XI polymorphism. Being a C/C homozygote is linked to a higher risk of venous thromboembolism, but your results show you are a heterozygote, which would mean that specific risk doesn't apply.
All in all, as I've said before, this is a complicated situation. We have a mountain of data but no way to review the full medical history or complete physical exams. Without the full picture, we're just spinning our wheels, and we still don't have a definitive answer as to what is actually happening.
Regarding the lab results you shared, I have to point out that having both MPO and PR3 antibodies present at the same time—as seen in your case—is quite unusual. When results look like this, we always have to rule out an underlying infection or certain medications that might trigger such a pattern. To be honest, I’m pretty skeptical about this being ANCA vasculitis, though I can't rule it out entirely. As for antiphospholipid syndrome, my stance remains unchanged: seeing only positive antibodies isn't enough to confirm that diagnosis.
I see you've also had coagulation tests performed, specifically checking factors VII and X, along with Protein C and S levels. Those levels are low, which makes sense given that you're taking Warfarin, as indicated by your INR. Since Warfarin works by blocking the production of factors II, VII, IX, and X, it's expected that these levels would drop while on the medication. I’m not entirely sure why these specific tests were requested. It would make perfect sense if factors VII and IX, or Protein C and S, had been tested *before* starting Warfarin—that's how you determine if there's an existing risk for clots or subsequent embolisms. Your entire clinical picture seems centered around clotting and emboli, yet you haven't mentioned them, and thrombosis or embolism isn't listed in your diagnoses. That's a bit confusing.
Furthermore, some genetic testing was done, though not for antiphospholipid syndrome as I suspected, but for thrombophilia. You were identified as a heterozygote for PAI-1, meaning you have the 4G/5G genotype. The highest risk for thrombosis lies with those who have the 4G/4G genotype; for someone with your 4G/5G profile, that risk is significantly lower.
I also noticed testing for the I/D polymorphism in intron 16 of the ACE gene. In individuals with the homozygous D/D genotype, there is a link to higher blood pressure and thickened vessel walls. What's puzzling here is that the report lists "I/D homozygote," which is a contradiction in terms. A homozygote is either I/I or D/D; I/D is a heterozygote. This suggests either a clerical error or an incomplete result.
Additionally, there was testing for a Factor XI polymorphism. Being a C/C homozygote is linked to a higher risk of venous thromboembolism, but your results show you are a heterozygote, which would mean that specific risk doesn't apply.
All in all, as I've said before, this is a complicated situation. We have a mountain of data but no way to review the full medical history or complete physical exams. Without the full picture, we're just spinning our wheels, and we still don't have a definitive answer as to what is actually happening.